Literature DB >> 8666518

The woodchuck: an animal model for hepatitis B virus infection in man.

M Roggendorf1, T K Tolle.   

Abstract

Since the discovery of woodchuck hepatitis virus (WHV) in 1978, the virus and its host, the American woodchuck, have been studied and used as the most suitable model for human hepatitis B virus infection. WHV is closely related to the human virus, having strong similarities in morphology, genome structure and gene products, replication, epidemiology, the course of infection and in the development of illness and hepatocellular carcinoma. Because of this high homology, the woodchuck model is used for many studies for the development of new vaccines, therapeutic vaccination and antiviral agents. In addition, the woodchuck system is used for investigation of molecular mechanisms of the viral life cycle, the mechanisms of carcinogenesis and cell infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8666518     DOI: 10.1159/000150418

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  28 in total

Review 1.  Hepatitis B virus taxonomy and hepatitis B virus genotypes.

Authors:  Stephan Schaefer
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 2.  The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection.

Authors:  Stephan Menne; Paul J Cote
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

3.  Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B.

Authors:  Tomasz I Michalak; Hong Zhang; Norma D Churchill; Torbjörn Larsson; Nils-Gunnar Johansson; Bo Oberg
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

4.  Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors.

Authors:  S Ren; M Nassal
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 5.  The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection.

Authors:  Michael Roggendorf; Anna D Kosinska; Jia Liu; Mengji Lu
Journal:  Cold Spring Harb Perspect Med       Date:  2015-10-28       Impact factor: 6.915

6.  Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis.

Authors:  L Aurisicchio; P Delmastro; V Salucci; O G Paz; P Rovere; G Ciliberto; N La Monica; F Palombo
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Helper-dependent adenoviral vector-mediated delivery of woodchuck-specific genes for alpha interferon (IFN-alpha) and IFN-gamma: IFN-alpha but not IFN-gamma reduces woodchuck hepatitis virus replication in chronic infection in vivo.

Authors:  Melanie Fiedler; Florian Rödicker; Valentina Salucci; Mengji Lu; Luigi Aurisicchio; Uta Dahmen; Li Jun; Olaf Dirsch; Brigitte M Pützer; Fabio Palombo; Michael Roggendorf
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  T-Cell response to woodchuck hepatitis virus (WHV) antigens during acute self-limited WHV infection and convalescence and after viral challenge.

Authors:  S Menne; J Maschke; M Lu; H Grosse-Wilde; M Roggendorf
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Pharmacodynamics of (-)-beta-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans.

Authors:  S J Hurwitz; B C Tennant; B E Korba; J L Gerin; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection.

Authors:  M Lu; G Hilken; J Kruppenbacher; T Kemper; R Schirmbeck; J Reimann; M Roggendorf
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.